QG3030 Advances Toward Phase 2 Readiness

Qgenetics has completed the core operational milestones required to advance QG3030 toward its next clinical stage. The team has aligned manufacturing, documentation, and clinical operations to support the upcoming development phase.

QG3030 remains a flagship oral osteoanabolic program within the company's Soft Aging pipeline. Recent work has focused on maintaining development speed while protecting quality and regulatory discipline.

Further updates will be shared as enrollment timelines and external collaboration milestones are finalized.